Pharmacovigilance Market to Hit USD 19.1 Billion by 2034 Amid Rising Regulatory Demands

The global Pharmacovigilance Market stood at USD 8.5 billion in 2024 and is set to expand steadily at a CAGR of 8.4%, reaching USD 19.1 billion by 2034, according to Prophecy Market Insights.

With adverse drug reaction (ADR) monitoring becoming a legal and ethical priority, biopharma companies are ramping up investments in real-time drug safety surveillance, post-marketing monitoring, and AI-integrated vigilance platforms.

Request Customization

Deep Dive: Market Segmentation

By Clinical Trial Phase:

• Preclinical
  
  

• Phase I–III
  
  

• Phase IV (Post-marketing vigilance drives significant revenue)
  
  

By Service Provider:

• In-house (Pharma companies expanding internal safety teams)
  
  

• Contract & Outsourcing (CROs growing in prominence)
  
  

By Reporting Type:

• Spontaneous Reporting
  
  

• Intensified ADR Reporting
  
  

• Targeted Spontaneous Reporting
  
  

• Cohort Event Monitoring
  
  

• EHR Mining
  
  

By End Users:

• Pharmaceutical Companies (lead adopters)
  
  

• Hospitals
  
  

• Other healthcare entities
  
  

Market Accelerators

Global Pharmacovigilance Regulations Tightening
Increased Drug Approvals & Clinical Trials
Integration of AI/ML in ADR Detection Systems
Growing Public Awareness About Drug Safety

Top Industry Players Driving Compliance and Innovation

Pharma safety is going digital, and the following tech-forward giants are leading the charge:

• Accenture
  
  

• Cognizant
  
  

• IBM Corporation
  
  

• Wipro Ltd.
  
  

• ICON PLC
  
  

• Capgemini
  
  

• ArisGlobal
  
  

• Foresight Group International AG
  
  

• Laboratory Corporation of America Holdings
  
  

• United BioSource Corporation
  
  

Regional Overview

• North America: Market leader with advanced regulatory frameworks and tech integration.
  
  

• Europe: Strong pharmacovigilance network due to EMA mandates.
  
  

• Asia Pacific: Fastest-growing region driven by increasing clinical trials and outsourcing trends.
  
  

Final Word

As the pharmacovigilance landscape evolves with digital monitoring and real-world data integration, companies that prioritize compliance and analytics will gain a decisive edge in patient safety and regulatory trust.